Cargando…

Clinical experience of SIB-IMRT in anal cancer and selective literature review

PURPOSE: To evaluate feasibility and outcome of our institutional SIB-IMRT schedule in patients with anal cancer and to selectively review the literature on different SIB-IMRT schedules. PATIENTS AND METHODS: Between 01/08-06/13 25 patients with biopsy proven squamous cell anal cancer were treated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Stefan, Glanzmann, Christoph, Bauerfeind, Peter, Stieb, Sonja, Studer, Gabriela, Brown, Michelle, Riesterer, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261589/
https://www.ncbi.nlm.nih.gov/pubmed/25199879
http://dx.doi.org/10.1186/1748-717X-9-199
_version_ 1782348299721768960
author Janssen, Stefan
Glanzmann, Christoph
Bauerfeind, Peter
Stieb, Sonja
Studer, Gabriela
Brown, Michelle
Riesterer, Oliver
author_facet Janssen, Stefan
Glanzmann, Christoph
Bauerfeind, Peter
Stieb, Sonja
Studer, Gabriela
Brown, Michelle
Riesterer, Oliver
author_sort Janssen, Stefan
collection PubMed
description PURPOSE: To evaluate feasibility and outcome of our institutional SIB-IMRT schedule in patients with anal cancer and to selectively review the literature on different SIB-IMRT schedules. PATIENTS AND METHODS: Between 01/08-06/13 25 patients with biopsy proven squamous cell anal cancer were treated in our institution with IMRT. Radiotherapy was delivered in two series using a SIB-IMRT schedule of 45 Gy/1.8 Gy to the primary tumor and adjacent pelvic lymph nodes and 38 Gy/1.52 Gy to elective nodes followed by an IMRT boost of 7×2 Gy = 14 Gy to the primary tumor and involved nodes (cumulative prescription dose: 59 Gy). RESULTS: Mean follow-up was 20 months (range: 4-68). The 2-year-local control, colostomy-free survival, distant metastases-free survival and overall survival rates were 92%, 92%, 92%, and 88%, respectively. Grade 3 acute skin toxicity was observed in 6 patients (24%). No high grade gastrointestinal or urinary acute toxicity occurred. Four patients required more than one day of treatment interruption due to acute toxicity. No grade 3 or higher late sequelae were observed. CONCLUSION: We present our institutional SIB-IMRT experience treating patients with anal cancer in two series using moderate single doses from 1.5-2.0 Gy. Our results, in terms of loco-regional outcome and toxicity, were comparable to other studies. The incidence of treatment interruptions was very low. Therefore this schedule appears to be safe for clinical use.
format Online
Article
Text
id pubmed-4261589
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42615892014-12-10 Clinical experience of SIB-IMRT in anal cancer and selective literature review Janssen, Stefan Glanzmann, Christoph Bauerfeind, Peter Stieb, Sonja Studer, Gabriela Brown, Michelle Riesterer, Oliver Radiat Oncol Research PURPOSE: To evaluate feasibility and outcome of our institutional SIB-IMRT schedule in patients with anal cancer and to selectively review the literature on different SIB-IMRT schedules. PATIENTS AND METHODS: Between 01/08-06/13 25 patients with biopsy proven squamous cell anal cancer were treated in our institution with IMRT. Radiotherapy was delivered in two series using a SIB-IMRT schedule of 45 Gy/1.8 Gy to the primary tumor and adjacent pelvic lymph nodes and 38 Gy/1.52 Gy to elective nodes followed by an IMRT boost of 7×2 Gy = 14 Gy to the primary tumor and involved nodes (cumulative prescription dose: 59 Gy). RESULTS: Mean follow-up was 20 months (range: 4-68). The 2-year-local control, colostomy-free survival, distant metastases-free survival and overall survival rates were 92%, 92%, 92%, and 88%, respectively. Grade 3 acute skin toxicity was observed in 6 patients (24%). No high grade gastrointestinal or urinary acute toxicity occurred. Four patients required more than one day of treatment interruption due to acute toxicity. No grade 3 or higher late sequelae were observed. CONCLUSION: We present our institutional SIB-IMRT experience treating patients with anal cancer in two series using moderate single doses from 1.5-2.0 Gy. Our results, in terms of loco-regional outcome and toxicity, were comparable to other studies. The incidence of treatment interruptions was very low. Therefore this schedule appears to be safe for clinical use. BioMed Central 2014-09-08 /pmc/articles/PMC4261589/ /pubmed/25199879 http://dx.doi.org/10.1186/1748-717X-9-199 Text en © Janssen et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Janssen, Stefan
Glanzmann, Christoph
Bauerfeind, Peter
Stieb, Sonja
Studer, Gabriela
Brown, Michelle
Riesterer, Oliver
Clinical experience of SIB-IMRT in anal cancer and selective literature review
title Clinical experience of SIB-IMRT in anal cancer and selective literature review
title_full Clinical experience of SIB-IMRT in anal cancer and selective literature review
title_fullStr Clinical experience of SIB-IMRT in anal cancer and selective literature review
title_full_unstemmed Clinical experience of SIB-IMRT in anal cancer and selective literature review
title_short Clinical experience of SIB-IMRT in anal cancer and selective literature review
title_sort clinical experience of sib-imrt in anal cancer and selective literature review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261589/
https://www.ncbi.nlm.nih.gov/pubmed/25199879
http://dx.doi.org/10.1186/1748-717X-9-199
work_keys_str_mv AT janssenstefan clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT glanzmannchristoph clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT bauerfeindpeter clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT stiebsonja clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT studergabriela clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT brownmichelle clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview
AT riestereroliver clinicalexperienceofsibimrtinanalcancerandselectiveliteraturereview